default author photo

Krisha McKee

Government of the United States of America - Vaccine Research Center

Bethesda, MD 20892-9806

United States

SCHOLARLY PAPERS

3

DOWNLOADS

101

TOTAL CITATIONS

3

Scholarly Papers (3)

1.

Structure of Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition

Number of pages: 43 Posted: 05 Aug 2019
National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Health Laboratory Services (NHLS) - Centre for HIV and STIs, University of the Witwatersrand, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Vaccine Research Center and National Institutes of Health - Vaccine Research Center
Downloads 40 (1,183,237)
Citation 1

Abstract:

Loading...

broadly neutralizing antibody, HIV-1 envelope trimer, multidonor antibody class, PCT64, PG9, PGDM1400, PGT145, tyrosine sulfation, V1V2-apex recognition

2.

Potent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys

Number of pages: 57 Posted: 02 Aug 2021
National Institutes of Health - Vaccine Research Center, Sanofi - Massachusetts, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - AIDS and Cancer Virus Program, Government of the United States of America - Vaccine Research Center, Sanofi - Massachusetts, Sanofi - Massachusetts, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, University of Pennsylvania - Perelman School of Medicine, University of Pennsylvania - Perelman School of Medicine, National Institutes of Health - Vaccine Research Center, affiliation not provided to SSRN, National Institutes of Health - Vaccine Research Center, Frederick National Laboratory for Cancer Research - AIDS and Cancer Virus Program, Government of the United States of America - AIDS and Cancer Virus Program, National Institutes of Health (NIH) - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Sanofi - Massachusetts, Sanofi and National Institutes of Health - Vaccine Research Center
Downloads 34 (1,263,436)
Citation 1

Abstract:

Loading...

3.

A Structure-Based Matrix Approach Yields Improved VRC01-Class Antibodies for HIV-1 Therapy and Prevention

Number of pages: 41 Posted: 05 Oct 2020
National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Laboratory of Immunoregulation, National Institutes of Health (NIH) - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Vaccine Research Center, Independent, National Institutes of Health - Vaccine Research Center, National Institutes of Health (NIH) - Vaccine Research Center, National Institutes of Health - Viral Pathogenesis Section, National Institutes of Health - Vaccine Research Center and National Institutes of Health - Vaccine Research Center
Downloads 27 (1,359,097)
Citation 1

Abstract:

Loading...

antibody VRC01, broadly neutralizing antibody, HIV-1 envelope trimer, polyreactivity, prophylaxis, treatment